Can an arthritis drug keep HIV in check without daily pills?
NCT ID NCT07209267
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether baricitinib, an FDA-approved drug for other conditions, can keep HIV under control after participants stop their usual antiretroviral therapy (ART). Twenty people with well-controlled HIV will take baricitinib alongside ART for 26 weeks, then continue baricitinib alone for up to 24 weeks. The goal is to see if baricitinib delays viral rebound and reduces the need to restart ART.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dr. Gavegnano's Laboratory
Atlanta, Georgia, 30322, United States
-
Grady Infectious Diseases Clinic (Ponce Center)
Atlanta, Georgia, 30308, United States